WO2005047532A1 - Improved method of performing genetic analyses on reproductive tract cell samples - Google Patents
Improved method of performing genetic analyses on reproductive tract cell samples Download PDFInfo
- Publication number
- WO2005047532A1 WO2005047532A1 PCT/AU2004/001587 AU2004001587W WO2005047532A1 WO 2005047532 A1 WO2005047532 A1 WO 2005047532A1 AU 2004001587 W AU2004001587 W AU 2004001587W WO 2005047532 A1 WO2005047532 A1 WO 2005047532A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell sample
- reproductive tract
- genetic
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Definitions
- This invention relates to methods of performing genetic analyses on cell samples taken from the reproductive tract of animals. It relates further to combinations of isolation/enrichment of cells from samples, the genetic identification and analysis of such cells and the automated processing of resultant data to enable high throughput genetic analysis and thus application in clinical practice. More particularly, this invention relates to high throughput enrichment of fetal cells from cervical samples, and in particular, Pap smears. In a particular form, this invention relates to use of fetal cells enriched from cervical samples for subsequent genetic analysis such as Down syndrome, sex and single gene defects and blood group testing.
- Particular embodiments of this invention utilize cell isolation procedures such as laser micro-dissection, magnetic and/or fluorescent activated cell sorting, singly and in combination, to enrich fetal cells to levels of purity that readily enable nucleic acid isolation for genetic analysis.
- Particular embodiments of this invention utilize techniques such as nucleic acid amplification and/or a variety of analysis techniques such as multiplex PCR to subsequently genetically analyse pooled or single cells.
- miscarriage 0.5-1%
- miscarriage 0.5-1%
- the miscarriage risk and high cost limit availability limits the availability of prenatal diagnosis to high risk mothers only.
- One less invasive alternative approach is to use maternal blood as a source of fetal cells for which many fetal cell enrichment methods have been developed, for example as described in United States Patent 5,629,147, United States Patent 5,646,004 and International Publication WO 98/02528.
- fetal cells can be isolated from cervical samples such as PAP smears using fluorescently labelled antibodies to remove maternal cells (negative enrichment) and extract fetal cells (positive enrichment) with subsequent genetic analysis in a similar manner to that performed for fetal cells in maternal blood, Immunology, 30 (2-3) pp.194- 201; Durrant et al., 1996 British Journal Of Obstetrics And Gynaecology, 103, (3), 219- 222).
- high throughput refers to the ability to process in excess of 50 samples per 24hr day.
- Fetal cells have been identified in cervical samples mainly by the identification of male cells within the sample, aneuploidy screening (the primary reason for prenatal diagnosis) cannot usually be performed nor diagnosis made if the fetus is female. This requirement has been partially overcome by recent advances such as multiplex fluorescent PCR which now allow multiple genetic analyses from single cells. However again results from fetal cells were not detected at a consistent and reliable enough level to be considered as a promising tool towards minimally invasive prenatal diagnosis.
- the invention generally provides a method of analysing the genetic characteristics of a reproductive tract cell sample taken from a subject, the method comprising the steps of:
- the subject is a mammal.
- the subject is a human being.
- the subject is a non-human mammal.
- the one or more target cells sought to be analysed via the use of the method are of embryonic origin.
- embryo or “embryonic” refers to an organism prior to birth and the expression includes all gestational stages (including fetal stages). It is particularly preferred that the one or more target cells are or comprise fetal cells.
- step (a) of the method comprises a non-invasive or substantially non- invasive procedure.
- the cell sample is taken by using an endocervical brush or a cytobrush to gather a cell sample from the subject by scraping the lining of the cervix or reproductive tract.
- the reproductive tract cell sample is: (a) a cervical cell sample; or
- a Pap smear procedure suitable for use in the method may be either: (a) a thin section Pap smear procedure; or
- the reproductive tract cell sample is obtained via a Pap smear procedure performed at between 5 and 31 weeks gestation. In that event, it is especially preferred that the method is performed in the first or second trimester of gestation.
- the cervical cell sample may additionally comprise one or more of the following:
- step (b) of the general method of the invention comprises an enrichment procedure, to isolate one or more target cells from other cells present in the reproductive tract cell sample.
- the enrichment procedure comprises either or both:
- the enrichment procedure comprises the use of one or more of the following techniques to differentiate target cells from non-target cells in the reproductive tract cell sample:
- the enrichment procedure comprises a differentiation step and the differentiation step comprises the use of one or more of the following: (a) exploiting physical differences between cells in the reproductive tract cell sample;
- the enrichment procedure comprises a differentiation step which involves the use of one or more of the following:
- the enrichment procedure used comprises the exploitation of immunological differences between the target and non-target cells in the reproductive tract cell sample, and those cells are differentiated by the use of at least one:
- an antibody is used to bind to antigens on or in the one or more target cells contained in the reproductive tract cell sample.
- the antibody is capable of binding to one or more embryonic cell antigens.
- the antibody is capable of binding to one or more of.
- the genetic analysis of the one or more target cells isolated from the reproductive tract cell sample comprises the use of either or both:
- the target cells to undergo genetic analysis are such that the nucleic acid(s) are contained within the target cell.
- the method also comprises the step of isolating one or more cell nuclei from the target cell (or cells) and the subsequent selection of one or more isolated nuclei.
- the amplification technique comprises or utilises one or more of the following: (a) polymerase chain reaction;
- the techniques (a) to (f) are carried out: sequentially, with technique (a) being used first; or in any other sequence.
- the genetic identification technique comprises or utilises one or more of the following: (a) DNA fingerprinting
- the results of the performing the method are analysed.
- the performance of at least one of the steps comprising the method is automated or semi- automated.
- the method is used to identify or diagnose the presence of at least one predetermined genetically mediated condition in the one or more target cells contained in or isolated from the reproductive tract cell sample.
- the predetermined genetically mediated condition may comprise one or more of the following:
- each genetic condition can be assessed individually, sequentially or simultaneously with any other genetic condition or combination of other genetic conditions.
- the use of the method leads to improved turn around times for receiving the results of analysis of cell samples.
- receiving the results of analysis of the reproductive tract cell sample is within 24 hours from the time of collecting the reproductive tract cell sample.
- the use of the method will lead to improvements in the number of analyses that can be carried out within a given time.
- the use of the method of the invention enables an analyst to perform the method at least 10 times in a period of 24 hours from the collection of a first reproductive tract cell sample from a subject.
- such an analyst is able to perform the method at least 20 times in a period of 24 hours from the collection of a first reproductive tract cell sample from a subject. Even more preferably, the analyst is able to perform the method at least 50 times in a period of 24 hours from the collection of a first reproductive tract cell sample from a subject.
- the invention provides a high throughput method of cell isolation including the step of enriching one or more fetal cells from a cervical sample.
- the invention also provides a high throughput method of obtaining a nucleic acid sample, .including the step of isolating one or more nucleic acids from one or more fetal cells that have been enriched from a cervical sample.
- the invention potentially improves the efficiency of whole genome amplification from single cells thus improving the potential for genetic analysis.
- this invention improves the robustness of whole genome amplification from single cells by reducing the incidence of allelic dropout, whole locus dropout and preferential amplification, thus improving the potential for genetic, and particularly quantitative, analysis.
- the invention provides higher throughput semi-automated and automated methods to increase sample throughput and increase cost-effectiveness.
- the invention provides a high throughput method of genetic analysis including the step of analyzing a nucleic acid obtained from one or more fetal cells that have been enriched from a cervical sample.
- the invention relates to the higher throughput use of one or more fetal cells enriched from a cervical sample for genetic analysis.
- the invention combines improvements over a number of steps (isolation, DNA fingerprinting and genetic analysis and data processing), which combine to give a significantly increased throughput sufficient for practical application.
- analyses also contemplated by the present invention include biochemical analysis, morphological analysis, histology, cytology, cell culture and the like as well as a variety of genetic analyses, including nucleic acid amplification methods such as PCR, CGH (comparative genome hybridization), whole genome amplification, SNPs (single nucleotide polymorphisms), FISH (fluorescent in situ hybridization) and the like.
- nucleic acid amplification methods such as PCR, CGH (comparative genome hybridization), whole genome amplification, SNPs (single nucleotide polymorphisms), FISH (fluorescent in situ hybridization) and the like.
- the invention relates to the high throughput use of one or more fetal cells enriched from a cervical sample for the isolation of a nucleic acid sample.
- the invention relates to high throughout use of a cervical sample for enrichment of one or more fetal cells for the isolation of a nucleic acid sample.
- the invention relates to high throughout use of a cervical sample for enrichment of one or more fetal cells for genetic analysis.
- the invention also relates to high throughout enrichment steps described herein to enrich fetal material from cervical samples.
- the invention also relates to the high throughout automation of steps described herein to enrich fetal material from cervical samples.
- the invention also relates to any combination of isolation/enrichment techniques with any combination of nucleic amplification and/or genetic identification techniques such as DNA identification, and/or genetic diagnosis and/or automated data analysis to allow sufficiently high throughput for practical application.
- the invention provides a method of fetal cell analysis including any combination of the steps of: i. enriching fetal cells from a Pap smear sample according to physical characteristics such as size, density, morphology and/or granularity, DNA content; and/or ii. positively selecting fetal cells from the cells enriched in step (i) and/or in using at least one primary/secondary antibody set that binds a fetal cell antigen. iii.
- Amplification of generic nucleic acid from isolated sample from step (ii) Genetic identification product from step (iii) using techniques such as DNA fingerprinting iv.
- Genetic analysis of product from steps (ii), (iii) and/or (iv) including but not limited to specific genetic analysis methods such as multiplex PCR, SNPs, CGH, FISH, RT-PCT and the like. It will be appreciated that steps (v) and (vi) can be combined into a single analysis procedure v. Detection of products from steps (iii), (iv) and/or (v) for example utilising nucleic acid separation technologies such as a DNA sequencer; vi. automated data processing to create analysis report from step (vi)
- the invention also apprehends the use of mico-fluidic devices in connection with the steps described above.
- the terms “comprise”, “comprises” and “comprising” are used as words of inclusion, so that a stated integer or group of integers may include one or more other non-stated integers or groups of integers.
- Fig 1 Represents a schematic summary of the method of the invention
- Fig 2 (Table 1) This table lists various STR marker sequences suitable for DNA identification and genetic analysis in accordance with the invention
- Fig 6 Illustrates the effect of various different cell solution filtration techniques on cell sorting, as demonstrated by dot plots generated by the use of the Beckman Coulter EXPO32 analysis software.
- Fig 7 Depicts the results of various Single Nucleotide Polymorphism (SNP) reactions, combining two SNPs (RhE and KEL)
- Fig 8 Depicts the results of various experiments on single Genomiphi . analysis on single cells, demonstrating the effect of incubation with Betaine on the reliability of the results obtained
- Fig 9 Depicts the results of single plex SNP reactions for the SNPs KEL and RhE.
- the present invention provides a variety of methods applicable to genetic analysis of fetal cells from maternal reproductive tract cell samples, and in particular, from cervical Pap smears. Such methods include the steps detailed previously, comprising cell isolation, nucleic acid isolation and amplification, genetic identification and analysis and automated data processing.
- the present invention is applicable to isolation or enrichment of other cells of non-maternal origin including, but not limited to, embryonic cells, sperm cells and any cells of cytotrophoblast or syncytiotrophoblast origin.
- the present invention is applicable to isolation or enrichment of other cells of non-maternal origin from a variety of other sources such as maternal blood, vaginal cells and the like.
- isolated material that has been removed from its natural state or otherwise been subjected to human manipulation.
- Isolated material may be substantially or essentially free from components that normally accompany it in its natural state, or may be manipulated so as to be in an artificial state together with components that normally accompany it in its natural state.
- enrichment in the context of cell isolation is meant that cells are obtained in a higher frequency of proportion compared to their frequency or proportion in a starting sample prior to enrichment. In this context enrichment is also taken to include 100% enrichment where the fetal cell or cells exist in the absence of maternal cells.
- fetal cells are enriched from a reproductive tract cell sample, which preferably, is a cervical sample.
- a reproductive tract cell sample which preferably, is a cervical sample.
- samples include and encompass any sample obtained from the endocervix inclusive of endocervical lavage, aspiration, swabbing; cytobrush samples; transcervical samples (TCCs) and Pap smears
- the cervical sample is a Pap smear.
- a Pap smear is a biological sample comprising one or more cells collected, obtained as a scraping from the cervix.
- a metal or plastic instrument such as a speculum is placed in the vagina to allow visualization of the interior of the vagina and the cervix.
- a sampling instrument such as a small wooden spatula is used to scrape the outside of the cervix and thereby obtain the cervical sample.
- Pap smears are a routine and safe screening procedure to find early warning signs of cervical cancer.
- the present invention provides a new use of Pap smears as a source of fetal cells for enrichment and subsequent analysis.
- said one or more cells typically comprises maternal cells and fetal cells.
- fetal cell isolation it is preferred that the Pap smear is obtained at between 5 and 31 weeks gestation.
- Cell enrichment may be performed by one or more high throughput cell isolation methods including density separation, complement-mediated lysis, flow cytometry, magnetic bead separation, panning, charge flow separation, laser microdissection and cell culture methods that promote selective propagation of cells to be enriched.
- high throughput cell isolation methods including density separation, complement-mediated lysis, flow cytometry, magnetic bead separation, panning, charge flow separation, laser microdissection and cell culture methods that promote selective propagation of cells to be enriched.
- Each cell enrichment method may be performed alone or in combination with one or more other methods to thereby achieve a desired level of cell enrichment or purity.
- protease treatment e.g. trypsin digestion
- cervical samples may be performed prior to density gradient enrichment.
- fetal cell enrichment may be achieved using physical characteristics such as size, density, DNA content, granularity and/or using antibodies directed to fetal antigens not expressed, or expressed at low levels, by maternal cells.
- fetal cells may be enriched by virtue of their non-expression of maternal or non-fetal antigens.
- fetal cell enrichment may be performed by negative depletion of maternal cells and/or positive selection of fetal cells according to antigen expression.
- Antigens that may be applicable to antibody-based enrichment include, but are not limited to, PAX-8, CD71 , y globin (fetal) and ⁇ globin (embryonic), glycophorin A, CD36, Fkl-1 , EPO-R, CDw50, CD45, human chorionic gonadotrophin (HCG), placental alkaline phosphatase, human placental lactogen, folate binding protein (LK26) and HLA antigens such as HLA-Class II, for each of which specific antibodies are readily available.
- Preferred antigens are human placental lactogen, placental alkaline phosphatase, human chorionic gonadotrophin, human folate binding protein (LK26), alphal feto-protein and PAX-8.
- antibody-based enrichment may utilize any technique that selects cells (i.e. positive selection) or depletes cells (i.e negative selection) according to antigen expression or non-expression, as the case may be.
- a non-exhaustive list includes panning, complement-mediated lysis, fluorescence-activated cell sorting (FACS) and magnetic activated cell sorting (MACS).
- FACS FACS can enrich samples by using physical cellular characteristics including but not limited to size, shape, granularity, relative DNA content and the like and/or fluorescently labelled antibodies.
- Cell Filtration Pre-filtering cell solutions before FACS analysis has two benefits, 1 : Filtration allows the large scale reduction/elimination of particular sized cells and/or debris. If a target cell is known to be of a particular size, these cells can be separated from solution and retained, thereby enriching their relative numbers. 2: Filtration prepares the cell sample for the purposes of FACS. It removes debris that can disrupt the flow of sample through the machine. It can also disrupt charge separation by adversely affecting the charging of individual droplets at the flow cell tip. Large debris can also be filtered out of solution. Large particles/cell clumps can clog the flow cell and need to be removed.
- cells of interest can be analysed, enriched and or isolated using the following parameters, either singly or in any combination:
- Forward Scatter Indicates the size of a cell or particle.
- Size Scatter Indicates the relative granularity of a cell or particle
- DNA Content The DNA-intercalating dye Propidium Iodide (PI) labels non-viable cells. To fluoresce, PI must be intercalated with DNA and excited by a 488nm laser. As such, the relative DNA content of a particle can therefore be ascertained by the intensity of signal from DNA-bound PI.
- PI Propidium Iodide
- Antibody labelling is carried out in two stages. The first stage involves the binding of primary antibodies that target particular cell surface antigens. These antibodies are generally species specific. The second stage involves the binding of fluorochrome-conjugated secondary antibodies. These antibodies bind the specific species from which the primary antibody was generated.
- the secondary antibody can be bound with a variety of fluorochromes that include, but are not limited to, FITC, Texas Red, PE, PerCP, PE-Cy7, PE-Cy5.
- fluorochromes include, but are not limited to, FITC, Texas Red, PE, PerCP, PE-Cy7, PE-Cy5.
- the laser light excites the bound fluorochrome, this signal is analysed and the cell can then be deflected for collection. Samples may also undergo negative and/or selection procedures. Positive selection is where cells of interest are labelled and those labelled cells are separated from unlabelled cells and the unlabelled cells discarded. Negative selection is similar but cells of interest are unlabelled and it is the labelled cells that are discarded
- Charge flow separation uses dielectrophoretic forces which occur on cells when a non-uniform electrical field interacts with field-induced electrical polarization. Depending on the dielectric properties of the cells relative to their suspending medium, these forces can be positive or negative, directing the cells toward strong or weak electrical field regiohs. Because cells of different types or in distinct biological states have different dielectric properties, differential dielectrophoretic forces can be applied to drive their separation into purified cell populations (Wang et al., 2000. Analytical Chemistry 72 832- 839).
- Fetal cell enrichment Fetal cells may be enriched by selective growth in the presence of appropriate cytokines and culture conditions that favor the selective proliferation of fetal progenitor cells over maternal cells. Selective growth may be performed after initial isolation or enrichment by one or more other enrichment methods.
- fetal nRBC's may be cultured after gradient enrichment and/or MACS enrichment in culture media containing many fetal NRBC growth factors (Bohmer et al., 1998, Br J Haematol 103 351-360). It is also contemplated that culture with fetal NRBC growth factors may stimulate a much higher basal proliferative capacity than mature progenitor cells and that this can be enhanced by addition of cytokine cocktails such as flt-3 ligand and thrombopoetin (Holzgreve et al., • 2000, Baillieres Best Pract Res Clin Obstet Gynaecol 14 709-722).
- cytokine cocktails such as flt-3 ligand and thrombopoetin
- a preferred embodiment of the invention provides a method of fetal cell isolation and analysis including the steps of:
- step (i) includes the sequential steps of:
- step (iv) includes the sequential steps of: (a) Higher throughput genetic analysis
- (c) genetic analysis whether by manual, semi-automated or automated means. Improved higher throughput automated data processing to create analysis report. Analysis reports can include indicators of diagnosis/screening markers, disease status as well as factors such as cell origin. Automated analysis provides the capacity to analyse many millions of analyses parameters extremely quickly and thus provide high throughput analysis.
- the improvements (and particularly, the combination of each of the improvements) in the above steps allow high throughput processing and analysis of embryonic cell samples
- enriched cells are for subsequent genetic analysis, biochemical analysis, morphological analysis, histology, cytology, cell culture and the like.
- genetic analysis and “genetic diagnosis” are used interchangeably and broadly cover detection, analysis, identification and/or characterization of isolated genetic material and includes and encompasses terms such as, but not limited to, genetic identification, genetic diagnosis, genetic screening, genotyping and DNA fingerprinting (also commonly known as STR profiling) which are variously used throughout this specification.
- nucleic acid designates single-or double-stranded mRNA, RNA, cRNA, RNAi and DNA inclusive of cDNA, genomic DNA and DNA-RNA hybrids.
- the nucleic acid may be contained within a cell, within the nucleus of a cell or isolated.
- a "polynucleotide” is a nucleic acid having eighty (80) or more contiguous nucleotides, while an “oligonucleotide” has less than eighty (80) contiguous nucleotides.
- a “SNP” is a single nucleotide polymorphism.
- a “primer” is usually a single-stranded oligonucleotide, preferably having 12-50 contiguous nucleotides which, for example, is capable of annealing to a complementary nucleic acid "template” and being extended in a template-dependent fashion by the action of a DNA polymerase such as Taq polymerase, RNA-dependent DNA polymerase or SequenaseTM.
- Genetic marker or “marker” is meant any locus or region of a genome. The genetic marker may be a coding or non-coding region of a genome.
- genetic markers may be coding regions of genes, non-coding regions bf genes such as introns or promoters, or intervening sequences between genes such as those that include polymorphisms (such as single nucleotide polymorphisms), tandem repeat sequences, for example satellites, microsatellites, short tandem repeats (STRs) and minisatellites, although without limitation thereto.
- polymorphisms such as single nucleotide polymorphisms
- tandem repeat sequences for example satellites, microsatellites, short tandem repeats (STRs) and minisatellites, although without limitation thereto.
- a “probe” may be a single or double-stranded oligonucleotide or polynucleotide, suitably labelled for the purpose of detecting complementary sequences in Northern or Southern blotting, for example. Genetic analysis may be performed by any method including, but not limited to, fluorescence in situ hybridization (FISH), primed in situ synthesis (PRINS) and nucleic acid sequence amplification, preferably in the form of multiplex fluorescent PCR amplification (MFPCR).
- FISH fluorescence in situ hybridization
- PRINS primed in situ synthesis
- MFPCR multiplex fluorescent PCR amplification
- FISH fluorescent in situ hybridization
- PRINS Primed In situ Synthesis
- multiplex amplification or “multiplex PCR” refers to amplification of a plurality of genetic markers in a single amplification reaction.
- MFPCR has been shown to be a reliable and accurate method for determining sex 5 (Salido et al., 1992, Am. J Human genetics 50 303; Findlay et al., 1994a, Human Reproduction, 9 23; Findlay et al.,. 1994b, Advances in Gene Technology: Molecular Biology and Human Genetic Disease. Vol 5, page 62.
- STR preferred genetic markers
- SNP markers preferred genetic markers.
- International Application PCT/AU02/01388 provides an extensive array of STR markers and primers together with MFPCR methodology to 15 successfully amplify multiple STR markers from limiting amounts of nucleic acid template.
- nucleic acid sequence amplification is not limited to PCR.
- Nucleic acid amplification techniques are well known to the skilled addressee, and also include ligase chain reaction (LCR) as for example described in Chapter 15 of
- NASBA NASBA 25 amplification
- Sooknanan et al.,1994, Biotechniques 17 1077 replicase amplification as for example described by Tyagi et al., 1996, Proc. Natl. Acad. Sci. USA 93 5395.
- nucleic acid sequence amplification techniques are not presented as an exhaustive list of techniques. Persons skilled in 30 the art will be well aware of a variety of other applicable techniques as well as variations and modifications to the techniques described herein.
- an "amplification product" refers to a nucleic acid product generated by a nucleic acid amplification technique.
- nucleic acid other than DNA
- the nucleic acid is DNA. More preferably, the nucleic acid is genomic DNA.
- SNP Single Nucleotide Polymorphisms
- SNP genotyping has multiple applications such as predictive medicine, personal medicine, forensic identification and pharmacogenomics. SNP genotyping has already been used to investigate a number of disorders such as cystic fibrosis, Factor V Leiden mutation, and factors such as A, B, O and Rh blood grouping.
- conventional SNP analysis is limited by the relatively high amount of extracted DNA usually required (up to 100ng) for analysis.
- genomic analysis there is increasing demand to both maximize data by performing multiple analyses and secondly to analyze minimum amounts of sample, even to the single cell level.
- multiplex SNP analyses can be performed routinely using a variety of techniques such as homolgous mass extension, multiplex single cell SNP analysis is still problematic. Although multiplex single cell SNP analysis has been published (Findlay et al, 2003, Todays Life Sciences 15 (5) 34-36), these techniques are not amenable to high throughput processing. This invention also anticipates that improvements to increase sample throughput and SNP processing will be combined with techniques and methods mentioned herein to provide improved SNP analysis from reproductive tract cells.
- Preferred sources of nucleic acids are mammals, preferably humans.
- the invention also contemplates genetic analysis of non-human samples such as from cows, sheep, horses, pigs and any other mammal including companion animals, sporting animals and livestock, although without limitation thereto. So that the invention may be readily understood and put into practical effect, reference is made to the following non-limiting examples.
- Particular embodiments of this invention include significant improvements such as improved lysis protocols and the use of particular enhancements to control the characteristics of the nucleic acid during amplification, particularly when combined with commercial whole genome amplification kits such as GE Healthcare Genomiphi kit - utilising the Phi29 DNA polymerase which has very high processivity and strand displacement properties or the Rubicon Genomics GenomePLex kit.
- commercial whole genome amplification kits such as GE Healthcare Genomiphi kit - utilising the Phi29 DNA polymerase which has very high processivity and strand displacement properties or the Rubicon Genomics GenomePLex kit.
- FACS buffer PBS supplemented with either 1 % BSA or 5% FBS and containing 0.05% NaN 3 .
- FACS buffer PBS supplemented with either 1 % BSA or 5% FBS and containing 0.05% NaN 3 .
- FACS buffer PBS supplemented with either 1 % BSA or 5% FBS and containing 0.05% NaN 3 .
- o Suspend the cell pellet from the final wash in 50 microliters FACS buffer (or more if more than one analysis is to be done on a single sample).
- Fetal cells may be isolated by any of the aforementioned cell isolation methods. In all cases samples from non-pregnant women are run as control cases to determine the base-line level of non-specificity.
- said one or more fetal cells are isolated by FACS sorting.
- Said one or more fetal cells may be isolated from any pregnant mammal.
- said one or more fetal cells are isolated from a pregnant human.
- CVS chorionic villus sampling
- a rapid, less-invasive and low cost method of prenatal diagnosis involves genetic diagnosis from fetal cells shed into the cervical sump at 6-20 weeks of gestation. These samples are obtained from the cervix by cytobrush in a manner identical to a PAP smear, which is similar to but significantly less invasive than invasive transcervical sampling.
- cytobrush in a manner identical to a PAP smear, which is similar to but significantly less invasive than invasive transcervical sampling.
- previous work has identified several major difficulties. Firstly the need to obtain the large numbers of fetal cells required for genetic diagnosis. Secondly the isolation of fetal cells from the cervical sample is extremely difficult as recent results suggest that fetal cells could be isolated and diagnosed in only -22% of cases due to the presence of "contaminating" maternal cells. Previous approaches have generally concentrated on isolating fetal cells by morphology or cell sorting.
- aneuploidy screening (the primary reason for prenatal diagnosis) cannot usually be performed nor diagnosis made if the fetus is female due to the risk of contamination causing misdiagnosis.
- said fetal cells are present in a maternal uterine cavity or endocervical canal sample, particularly a transcervical sample.
- Methods of isolating fetal cells include cervical cotton swab, cytobrush, aspiration of cervical mucus, lavage of the endocervical canal and uterine lavage.
- Samples can be obtained from transcervical aspiration of mucus from just above the internal os or the lower uterine cavity.
- Lavage is generally conducted with a saline wash, but other isotonic solutions are suitable.
- endocervical lavage with 5-10ml or intrauterine lavage with 10-20ml saline provides sufficient fetal cells upon separation from maternal cells.
- the sample may be collected using a combination of methods.
- cell samples are isolated from a female human in the first trimester of pregnancy or when the fetus is between 6 to 17 weeks gestation.
- the sample can be in any solution which maintains cell integrity and minimizes cell lysis or damage, preferably a physiological solution, or more preferably, a saline solution or tissue culture medium with or without the addition of sera.
- the sample is preferably stored at 0°C to 4°C until use to minimize the number of dead cells, cell debris and cell clumps.
- clumps of cells are preferably treated to obtain a suspension of single cells.
- the clumps may be separated by techniques known to a skilled person, such as enzymatic, chemical or mechanical separation.
- enzymatic separation may utilise protease or trypsin.
- Chemical separation may utilise acetyl cysteine and mechanical separation may involve gentle teasing, aspiration or micromanipulation.
- the number of fetal cells in the sample varies depending on factors including the age of the fetus, method of sampling, number and frequency of samplings, the vigour of sampling and the volume aspirated.
- Maternal uterine cavity or endocervical canal samples typically contain at least two main types of nucleated fetal cells: cytotrophoblasts and syncytiotrophoblasts cells.
- Fetal cells can be isolated either by selecting fetal cells from maternal cells (positive selection) or isolating the maternal cells from the fetal cells (negative selection) or most preferably a combination of both.
- the nucleated fetal cells are retained in the purified sample.
- the cells are labelled with an antibody for a common cell type antigen that should not be significantly expressed in fetal cells.
- the negative selection procedures sorts those cells that are labelled with the negative selection antibody and retains the unlabelled cells.
- the unlabelled cells will consist of fetal cells as well as maternal cells that may not express the antigen or fail to bind to the antibody, hence the reason for serial selections. .
- More preferred as a protein supplement is about 5% autologous plasma, which can be harvested from a purified blood sample and is non-immunogenic.
- the cells of the sample are labelled with fluorescent antibodies specific for the antigens encoded by at least one maternal locus, selected as described previously.
- the antibodies can be polyclonal or monoclonal, preferably monoclonal. Preparation of polyclonal and monoclonal antibodies for an antigen of interest is well known. Furthermore, there is a vast supply of potentially useful antibodies, such as to human HLA antigens, that are commercially available or available from hybridoma depositories such as the ATCC.
- HLA antigen-specific antibodies are commercially available.
- HLA Class 1 loci A, B and C
- Class 11 DR and DQ loci are determined by serological methods. Therefore, antibodies • specific for those antigens are readily available.
- Sources of HLA antigen-specific antibodies include Genetic Systems (Seattle, Wash.) and C6 Diagnostics (Mequon, Wis.). Blood group antigens are also determined serologically and the antibodies are commercially available.
- the antibody is labelled with a dye that facilitates, cell sorting, particularly a fluorochrome, Suitable dyes for FACS analysis and/or separation are well known in the art.
- dyes are described in Practical Flow Cytometry (Second Edition), supra, at pages 11 5-198 and in Chapter 5 of Current Protocols in Immunology, supra.
- Preferred dyes are fluorochromes including fluorescein (e.g., fluorescein isothiocyanate-FITC), rhodamine (e.g., tetramethylrhodamine isothiocyanate-TRITC), phycoerythrin (PE), allophycocyanin (APC) and Texas Red (Molecular Probes, Eugene, Oreg.).
- cells can be labelled with antibodies for antigens expressed by four alleles.
- the antibodies are specific for both antigens expressed by the alleles of two maternal HLA loci.
- Maternal cells are labelled with all four fluorochromes.
- Fetal cells are labelled with two of the four fluorochromes when none of the nontransmitted maternal alleles is inherited from the father.
- the fetal cells remain distinguishable from the maternal cells even when the fetus inherits one of the nontransmitted maternal alleles from the father.
- a second staining is only necessary when the fetus inherits both nontransmitted maternal alleles from the father.
- using the additional dyes increases the likelihood that the fetus did not inherit each of the maternal alleles.
- Fetal cells are only indistinguishable from maternal cells by the method of the present invention in the case where the fetus inherits all six non-transrnitted maternal alleles from the father.
- cells are preferably incubated at about 4°C to maintain cell integrity. Incubation for about 30 minutes at 4°C is usually sufficient for substantially complete antibody binding.
- the sample is preferably mixed, as by using a hematology blood rocking device, during the incubation to ensure contact of the antibodies with the cells. Preferably, the incubation is performed in the dark when using a fluorochrome label. Secondary reactions (e.g. incubation of fluorochrome-labelled avidin with biotin labelled cells) are performed in the same manner.
- an additional selection criterion is DNA content.
- Fetal cells having greater than 2C DNA content can be determined using a number of vital- staining fluorochromes such as the Hoechst dyes, DAP1 (4-6-diamidino-2-phenylindole), hydroethidine and 7-aminoactinomycin D (7AMD).
- the fluorochrome used depends on the labels used to select the fetal cells.
- a second laser capable of emitting UV light is required to excite Hoechst and DAPI dyes.
- Each of the above-described dyes can be used with FITC and PE.
- the ability of the cell sorter to separate maternal and fetal cells ultimately depends on the percentage of fetal cells in the sample.
- the fetal cells should constitute about 0.001 % of the maternal cells or greater.
- the sample contains
- fetal cells post-sorting 80%, more preferably 90% fetal cells post-sorting.
- the sorted cells can be plated for subsequent analysis.
- cell suspensions containing an individual cell can be isolated within a preselected volume of suspension medium by limiting dilution. Drops containing individual cells can then be placed in suitable pre-made containers (e.g. 96 well plates) for subsequent nucleic acid amplification and/or analysis.
- analysis can be performed using a single, unambiguously identified fetal cell, identified for example by DNA fingerprinting.
- identifying monozygosity indicative of the presence of a monogenic disease
- a mixed cell population containing minimal fetal material including as few as one fetal cell in ten cells.
- the separated cells can be washed twice in a physiologic buffer and resuspended in an appropriate medium for any subsequent analysis to be performed on the cells.
- enriched cells may also be tested for particular genetic markers not present in the maternal samples such as Y-chromosome markers if the embryos is male.
- genetic markers not present in the maternal samples such as Y-chromosome markers if the embryos is male.
- use of such techniques are limited when the gender of the embryo is not previously known.
- the fetal cells can be used in the same manner as fetal cells obtained by other methods such as anmiocentesis and chorionic villus biopsy.
- the cells can be used as a source of DNA for analysis of the fetal alleles, as by polymerase chain amplification. PCR analysis methods may be used to detect, for example, fetal sex, beta thalassemia, phenylketonuria (PKU), and Duchennes muscular dystrophy.
- the cells can be cultured in the same manner as biopsy materials for karyotyping analyses. However, the incubation period may be significantly shortened if a DNA content of greater than or equal to 2C is used as a selection criterion. 7.4 Isolation of antibody labelled fetal cells by FACS
- samples from non-pregnant women are run as control cases to determine the base-line level of non-specificity.
- genetic analysis of fetal cells isolated from pap smears preferably requires a number of serial enrichment strategies in order to provide a reliable source of relatively uncontaminated fetal, cells.
- Initial FACS enrichment strategies usually identify cells using physical characteristics such as density, charge or size. Although single cycles are not highly specific they do reduce target cell loss and are relatively low in cost, therefore multiple cycles, either on physical or fluorescent characteristics, are utilised to maximise specificity whilst maintaining cellular yield.
- Secondary enrichment strategies such as antibody staining will often identify cells using specific cellular traits. Primary and secondary enrichment strategies work in unison to provide a reliable source of uncontaminated fetal cells yet achieve maximum yield. Performing multiple cycles to improve purity and/or yield are not significant time or sample limiting steps. 7.5 Cell processing with FACS
- Cells were scanned by the Altra flow cytometer (Beckman Coulter) and the resultant data analysed by the accompanying Altra EXPO 32 Multicomp analysis software (Beckman Coulter), using combinations of analysis parameters of forward scatter, side scatter, relative DNA content and antibody labelling data. Cells of interest were determined from two-dimensional scatter graphs and gated in the Multicomp software. The instrument was then directed to sort individual cells within these gates into a 96-well plate containing 1?l of Lysis Buffer (200mM potassium hydroxide/50mM Dithiothretol, 0.001% SDS) in each well using the Autoclone module.
- Lysis Buffer 200mM potassium hydroxide/50mM Dithiothretol, 0.001% SDS
- the plate was sealed with a Qiagen Tape Pad, spun down in a plate centrifuge and incubated at 65°C for 10 minutes. 1?1 neutralising buffer (200mM HCI/200mM beta- mercaptoethanol) was then added. Cells were stored at -20°C until MFPCR.
- PCR product was processed using Ammonium. acetate/Ethanol Clean-up. Post clean-up processing involved adding 2uL of cleaned-up product to 3uL loading buffer (Amersham Biosciences, Piscataway, New Jersey). Samples were then heated to 90 degrees for 60 seconds and placed immediately on ice. Analysis was completed using the Megabace 1000 capillary electrophoresis system with Genetic Profiler Version 1.5 software (Amersham Biosciences, Piscataway, New Jersey). Injection parameters were - 3kV for 45 seconds and run parameters were -1 OkV for 75 minutes at 44°C.
- the STR is an additional band to that found in the maternal fingerprint i.e. consistent with maternal signal. It is not consistent with a stutter band or artefact peak and that it is the same base pair size as bands identified as fetal for the same locus within other isolations from the same patient.
- Protocols for enrichment and diagnosis of fetal cells from the cervix must be consistently successful, robust and inexpensive if the techniques are to become an alternative to invasive procedures such as amniocentesis or chorionic villus sampling.
- Previous inventions and work has been significantly limited by a variety of factors including: obtaining sufficient cells; isolation of fetal cells from the sample; genetic identification of cells to determine fetal source; genetic diagnosis from small cell numbers and sample collection.
- this invention provides incremental improvements to multiple steps and combines them into a high throughput method allowing widespread application for the first time.
- this invention may also be considered as a complementary technique to other non-invasive or minimally invasive tests such as biochemical screening and ultrasound screening offered to pregnant women during the first trimester of pregnancy (Daryani et al., 2000, J. Obstet. Gynecol.
- MFPCR DNA fingerprinting using MFPCR was used to confirm cell origin of the fluorescent cells from each antibody set and patient. This MFPCR technique has the advantage of being highly discriminating for cell origin even when applied to very close relatives such as mother and baby.
- FISH analysis can only identify fetal cells if they are aneuploid or originate from a male fetus (Fejgin et al., 2001 , supra) - this is an important and considerable limitation to the use of such techniques for prenatal diagnosis.
- Other studies use PCR analysis to detect disorders however in most cases this is limited to the gene analysed and quantitative variations in the maternal and fetal alleles, for example RH(D) analysis (Tutschek et al., 1995, Prenatal Diagnosis 15 951 ).
- MFPCR has the advantages of overcoming these limitations, as it is not limited by sex or individual gene alleles. MFPCR has an extremely high level of discrimination between closely related individuals, can be performed on single cells and provides multiple diagnoses within a single reaction.
- MFPCR was used to accurately determine the presence of fetal cells in a mixed fetal/maternal sample. For these reasons we suggest that MFPCR be considered the preferred method of choice when performing prenatal genetic diagnosis from pap smear samples. 7.8 Single Cell Lysis Protocol:
- Lysis Buffer 200mM KOH, 50mM DTT, 0.001 % SDS is added to a single cell in a 0.2ml tube or plate.
- Neutralising Buffer 200mM HCI, 200mM beta- mercaptoethanol
- PCR product was processed using Ammonium acetate/Ethanol Clean-up. Post clean-up processing involved adding 2uL of cleaned-up product to 3uL loading buffer (Amersham Biosciences, Piscataway, New Jersey). Samples were then heated to 90 ' degrees for 60 seconds and placed immediately on ice. Analysis was completed using the Megabace 1000 capillary electrophoresis system with Genetic Profiler Version 1.5 software (Amersham Biosciences, Piscataway, New Jersey). Injection parameters were - 3kV for 45 seconds and run parameters were -1 OkV for 75 minutes at 44°C.
- MFPCR can be performed on single cells and provides multiple diagnosis within a single reaction.
- MFPCR was used to accurately determine the presence of fetal cells isolated from a mixed fetal/maternal sample.
- samples highly enriched in fetal cells >90%) can be produced even though an uncontaminated source of fetal cells from pap smears (i.e. isolation of 100% fetal cells) may not be possible.
- Single fetal cells can then be easily isolated and used to screen for genetic traits. For this reason, and the ability to test for multiple probes, MFPCR may be considered the method of choice when performing prenatal genetic diagnosis from pap smear samples.
- SNP Single Nucleotide Polymorphisms
- SNP genotyping has multiple applications such as predictive medicine, personal medicine, forensic identification and pharmacogenomics
- conventional SNP analysis is limited by the relatively high amount of extracted DNA usually required (up to 100ng) for analysis.
- genomic analysis there is increasing demand to both maximize data by performing multiple analyses and secondly to analyze minimum amounts of sample, even to the single cell level.
- multiple SNP analyses can be performed routinely, the degree if sensitivity is still far from single cell level analysis.
- Multiplex single cell SNP analysis has been problematic and again is not amenable to the high throughput processing required of clinical application.
- SNP genotyping can be used to identify genetic regions associated with a disease phenotype, allowing researchers to target particular areas of interest and begin to reveal relevant genes associated with a disease. SNP patterns from a large group of affected individuals can be compared to those of unaffected individuals. These association studies can detect differences in the SNP patterns of the two groups, thereby indicating potentially important SNPs and thus genetic regions for further study. Eventually SNP profiles that are characteristic of a variety of diseases will become established. Defining and understanding the role of genetic factors in disease will also allow researchers to better evaluate the role that non-genetic factors - such as behaviour, diet, lifestyle, and physical activity - have on disease.
- SNP genotyping has already been used to investigate a number of disorders such as cystic fibrosis, Factor V Leiden mutation, and factors such as A, B, O and Rh blood grouping.
- SNP genotyping is undertaken in six main stages: PCR, Post-PCR cleanup, SNP primer extension reaction, final cleanup, SNP product sizing and analysis.
- Isolated fetal cells were processes in a multiplex SNP reaction consisting of oligonucleotides for specific SNPs such as Kell, Rh etc. Each 25 ⁇ l reaction contained 25pmol forward and reverse primers, 1 X PCR buffer, 5nM each dNTP (Gibco, Life Technologies, Melbourne, Australia) and 1 unit Qiagen HotStarTaq (Qiagen, Melbourne, Australia). PCR conditions were 95°C for 15 minute denaturation followed by 45 cycles of 20 sees at 94°C, 60°C then 72°C then followed by a two minute extension at 72°C.
- Lysis Buffer 200mM KOH, 50mM DTT, 0.001% SDS
- Tubes or plates are then stored at -2Q°C until needed for normal SNP PCR.
- Post PCR cleanup removes excess dNTPs and residual primers before primer extension and commonly uses SAP (shrimp alkaline phosphatase) and EXOI (exonuclease I) protocols.
- SAP shrimp alkaline phosphatase
- EXOI exonuclease I
- a final clean-up step is to remove excess terminators and desalts the samples prior to electrokinetic injection.
- AutoSeq96 columns (Amersham Biosciences) are used as per following protocol.
- SNP product sizing Add 2.5ul multiple injection marker (MIM, Amersham Biosciences) to 497.5ul loading solution then dispense 5 ⁇ l into each well. Load LPA matrix (Amersham, Biosciences) and rerun as per manufacturers protocol. Perform cycles of sample injection then two-minute electrophoresis interval and repeat upto twelve times. Enter sizing and SNP parameters into Snupe and Instrument Control Manager.
- MIM multiple injection marker
- Amersham Biosciences Amersham Biosciences
- Single cell is picked into a 0.2ml tube or 0.2ml well of a 96-well plate. Lysis is carried out as previously described. To the ⁇ 2?l of lysate, 1?l of enhancer (such as 5M Betaine) and 9?l of Genomiphi (GE Healthcare) Sample Buffer is added and heated to 95°C for 3 minutes then cooled to 4°C on ice. 91 of Genomiphi Reaction Buffer and 1?l of Genomiphi enzyme is then added to the lysate/sample buffer mix. The tube is then incubated at 30°C for 18hrs, followed by a 10 minute 65°C step to denature the enzyme. The reaction product is then cleaned using Ammonium Acetate/Ethanol precipitation. Product is re-suspended in 20I and 21 is taken for downstream reactions. Results of single cell-Genomiphi are shown in Figure 7.4 Discussion
- This specific example of the invention demonstrates that for the first time, efficient enrichment of embryonicl cells from Pap smears can be performed using an improved method (and particularly, a combination of improved methods), including FACS, nucleic acid amplification, genetic analysis, and the other techniques discussed earlier.
- improved methods including FACS, nucleic acid amplification, genetic analysis, and the other techniques discussed earlier.
- the combinations of this technology with improved automated procedures for genetic identification and analysis have been applied to create an improved method which allows automated high throughput system to maximize cost effectiveness and thus offer the first practical non-invasive prenatal analysis application.
- the cost advantages that the inventors anticipate will arise from the use of the invention include:
- the method lends itself potentially to a high degree of automation, thereby reducing the need for human involvement in performing those aspects which are capable of being automated; •
- the increased speed of performing the method (through (A) reduced turnaround time for an analysis and (B) increased "throughput" [ie, the increase in the number of samples that can be processed in any given time]) means that the cost of analysing a sample in any given period of time is reduced;
- the method entails the possibility of integrating a DNA fingerprinting system and a diagnostic system, which reduces the need for multiple testing of subjects;
- the method entails the potential for conducting multiple tests simultaneously on a subject. This avoids the need to test a single subject more than once. The inventors believe that this embodiment therefore represents a substantial advance compared to prior art and confirms that non-invasive prenatal diagnosis from pap smears can be automated to provide the high through capability required for clinical application.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004289714A AU2004289714A1 (en) | 2003-11-17 | 2004-11-17 | Improved method of performing genetic analyses on reproductive tract cell samples |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003906304A AU2003906304A0 (en) | 2003-11-17 | High throughput isolation and genetic analysis of prenatal samples | |
AU2003906304 | 2003-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005047532A1 true WO2005047532A1 (en) | 2005-05-26 |
Family
ID=34578155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2004/001587 WO2005047532A1 (en) | 2003-11-17 | 2004-11-17 | Improved method of performing genetic analyses on reproductive tract cell samples |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005047532A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007147079A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Rare cell analysis using sample splitting and dna tags |
EP2029778A2 (en) * | 2006-06-14 | 2009-03-04 | Living MicroSystems, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
WO2009103110A1 (en) | 2008-02-18 | 2009-08-27 | Genetic Technologies Limited | Cell processing and/or enrichment methods |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
WO2012154614A1 (en) * | 2011-05-06 | 2012-11-15 | Celula, Inc. | Methods and compositions for isothermal whole genome amplification |
CN105506066A (en) * | 2014-09-26 | 2016-04-20 | 深圳华大基因科技有限公司 | Cell identification method for new generation of noninvasive prenatal diagnosis field |
CN105755545A (en) * | 2010-12-27 | 2016-07-13 | 艾比斯生物科学公司 | Nucleic Acid Sample Preparation Methods And Compositions |
US9447467B2 (en) | 2009-04-21 | 2016-09-20 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
US9493831B2 (en) | 2010-01-23 | 2016-11-15 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
CN113025558A (en) * | 2021-02-23 | 2021-06-25 | 王姗 | Auxiliary reagent for detecting desquamation cells of precancerous lesions of oral mucosa |
EP4144834A4 (en) * | 2021-05-20 | 2023-09-27 | Guangzhou Hybribio Medicine Technology Ltd. | Method for separating placental trophoblast cells from exfoliated cervical cells of pregnant woman |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996017085A1 (en) * | 1994-11-30 | 1996-06-06 | Thomas Jefferson University | Methods for identifying fetal cells |
WO2003020986A1 (en) * | 2001-09-06 | 2003-03-13 | Monash University | Method of isolating cells and uses thereof |
WO2004076653A1 (en) * | 2003-02-28 | 2004-09-10 | The University Of Queensland | Fetal cell isolation and enrichment |
-
2004
- 2004-11-17 WO PCT/AU2004/001587 patent/WO2005047532A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996017085A1 (en) * | 1994-11-30 | 1996-06-06 | Thomas Jefferson University | Methods for identifying fetal cells |
WO2003020986A1 (en) * | 2001-09-06 | 2003-03-13 | Monash University | Method of isolating cells and uses thereof |
WO2004076653A1 (en) * | 2003-02-28 | 2004-09-10 | The University Of Queensland | Fetal cell isolation and enrichment |
Non-Patent Citations (4)
Title |
---|
ADINOLFI M. ET AL.: "Fetal cells in transcervical samples at an early stage of gestation", J. HUM. GENET., vol. 46, no. 3, 2001, pages 99 - 104, XP002641944 * |
HOLZGREVE W. ET AL.: "fetal cells in cervical mucus and maternal blood", BAILLIERE'S CLINICAL OBSTETRICS AND GYNECOLOGY, vol. 14, no. 4, 2000, pages 709 - 722, XP008081646, DOI: doi:10.1053/beog.1999.0106 * |
KINGDOM J. ET AL.: "Detection of trophoblast cells in transcervical samples colected by lavage or cytobrush", OBSTETS AND GYNAECOL, vol. 86, no. 2, 1995, pages 283 - 288, XP002986612, DOI: doi:10.1016/0029-7844(95)00127-D * |
SCHUELER ET AL.: "Enrichment and identification of fetal trophoblast cells from first trimester maternal cervical lavage and uterine blood specimens", PLACENTA, vol. 22, 2001, pages 688 - 701, XP002351396, DOI: doi:10.1053/plac.2001.0705 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10041119B2 (en) | 2006-06-14 | 2018-08-07 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
WO2007147079A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Rare cell analysis using sample splitting and dna tags |
EP2024513A4 (en) * | 2006-06-14 | 2010-01-20 | Artemis Health Inc | Rare cell analysis using sample splitting and dna tags |
EP2029778A4 (en) * | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
EP3425058A1 (en) * | 2006-06-14 | 2019-01-09 | Verinata Health, Inc | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
EP2029778A2 (en) * | 2006-06-14 | 2009-03-04 | Living MicroSystems, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11261492B2 (en) | 2006-06-14 | 2022-03-01 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
EP2024513A2 (en) * | 2006-06-14 | 2009-02-18 | Living MicroSystems, Inc. | Rare cell analysis using sample splitting and dna tags |
US10435751B2 (en) | 2006-06-14 | 2019-10-08 | Verinata Health, Inc. | Methods for the diagnosis of fetal abnormalities |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
EP2250497A4 (en) * | 2008-02-18 | 2011-08-24 | Genetic Technologies Ltd | Cell processing and/or enrichment methods |
EP2250497A1 (en) * | 2008-02-18 | 2010-11-17 | Genetic Technologies Limited | Cell processing and/or enrichment methods |
WO2009103110A1 (en) | 2008-02-18 | 2009-08-27 | Genetic Technologies Limited | Cell processing and/or enrichment methods |
US8296076B2 (en) | 2008-09-20 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuoploidy by sequencing |
US10669585B2 (en) | 2008-09-20 | 2020-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8682594B2 (en) | 2008-09-20 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9404157B2 (en) | 2008-09-20 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9353414B2 (en) | 2008-09-20 | 2016-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9447467B2 (en) | 2009-04-21 | 2016-09-20 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
US10718020B2 (en) | 2010-01-23 | 2020-07-21 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US9493831B2 (en) | 2010-01-23 | 2016-11-15 | Verinata Health, Inc. | Methods of fetal abnormality detection |
CN105755545A (en) * | 2010-12-27 | 2016-07-13 | 艾比斯生物科学公司 | Nucleic Acid Sample Preparation Methods And Compositions |
CN105755545B (en) * | 2010-12-27 | 2019-05-03 | 艾比斯生物科学公司 | The preparation method and composition of nucleic acid samples |
WO2012154614A1 (en) * | 2011-05-06 | 2012-11-15 | Celula, Inc. | Methods and compositions for isothermal whole genome amplification |
CN103687961A (en) * | 2011-05-06 | 2014-03-26 | 赛卢拉有限公司 | Methods and compositions for isothermal whole genome amplification |
EP2705166A4 (en) * | 2011-05-06 | 2014-12-17 | Celula Inc | Methods and compositions for isothermal whole genome amplification |
EP2705166A1 (en) * | 2011-05-06 | 2014-03-12 | Celula Inc. | Methods and compositions for isothermal whole genome amplification |
CN103687961B (en) * | 2011-05-06 | 2022-11-22 | 赛雷纳(中国)医疗科技有限公司 | Methods and compositions for isothermal whole genome amplification |
US10041106B2 (en) | 2011-05-06 | 2018-08-07 | Progenity, Inc. | Methods and compositions for isothermal whole genome amplification |
CN105506066B (en) * | 2014-09-26 | 2021-04-30 | 深圳华大基因细胞科技有限责任公司 | Cell identification method for new-generation noninvasive prenatal diagnosis field |
CN105506066A (en) * | 2014-09-26 | 2016-04-20 | 深圳华大基因科技有限公司 | Cell identification method for new generation of noninvasive prenatal diagnosis field |
CN113025558A (en) * | 2021-02-23 | 2021-06-25 | 王姗 | Auxiliary reagent for detecting desquamation cells of precancerous lesions of oral mucosa |
EP4144834A4 (en) * | 2021-05-20 | 2023-09-27 | Guangzhou Hybribio Medicine Technology Ltd. | Method for separating placental trophoblast cells from exfoliated cervical cells of pregnant woman |
JP7368642B2 (en) | 2021-05-20 | 2023-10-24 | 広州凱普医薬科技有限公司 | How to isolate placental trophoblast cells from cervical exfoliated cells of pregnant women |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6310804B2 (en) | Non-invasive prenatal diagnosis method and apparatus | |
EP1613743B1 (en) | Fetal cell isolation and enrichment | |
JPH05501612A (en) | Non-invasive methods for fetal DNA isolation and detection | |
JP2006523100A (en) | Noninvasive prenatal genetic diagnosis using transcervical cells | |
JP2005500861A (en) | Method for isolating cells and use thereof | |
WO2005047532A1 (en) | Improved method of performing genetic analyses on reproductive tract cell samples | |
JP2010500018A (en) | Blood cell isolation | |
Bischoff et al. | Prenatal diagnosis with use of fetal cells isolated from maternal blood: five-color fluorescent in situ hybridization analysis on flow-sorted cells for chromosomes X, Y, 13, 18, and 21 | |
EP3143410B1 (en) | Preparation of fetal nucleated red blood cells (nrbcs) for diagnostic testing | |
Holzgreve et al. | Fetal cells in cervical mucus and maternal blood | |
Goldberg | Fetal cells in maternal circulation: progress in analysis of a rare event. | |
WO2000075647A1 (en) | System and method for prenatal diagnostic screening | |
Goumy et al. | Chorionic villus sampling (CVS) and fluorescence in situ hybridization (FISH) for a rapid first‐trimester prenatal diagnosis | |
JP2016067268A (en) | Non-invasive methods for determining fetal chromosomal aneuploidy | |
Tang et al. | Research progress in isolation and enrichment of fetal cells from maternal blood | |
US20230258663A9 (en) | Filtration-based methods for preparing fetal nucleated red blood cells (nrbcs) for diagnostic testing | |
AU2004289714A1 (en) | Improved method of performing genetic analyses on reproductive tract cell samples | |
US20170206310A1 (en) | Noninvasive discrimination method and discrimination system of chromosomal heteroploidy of fetus | |
Sonek et al. | Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform | |
Vossaert et al. | Cell-Based Noninvasive Prenatal Testing: A Promising Path for Prenatal Diagnosis | |
Chiu et al. | Non-invasive prenatal diagnosis: on the horizon? | |
Skinner et al. | Analysis of fetal DNA in the maternal venous blood for abnormalities of chromosomes 13, 16, 18 and 21 in first-trimester spontaneous miscarriage | |
Maktabi et al. | Cell-based Noninvasive Prenatal Testing (cbNIPT)—A Review on the Current Developments and Future Prospects | |
AU2004215324B2 (en) | Fetal cell isolation and enrichment | |
Holzgreve et al. | Fetal cells in maternal Blood. An Overview of the Basel Experience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004289714 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547622 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004289714 Country of ref document: AU Date of ref document: 20041117 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004289714 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase |